Literature DB >> 28361459

Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Vladimír Hrabovský1, Victoria Takáčová2, Eva Schréterová2, Lydia Pastvová2, Zuzana Hrabovská3, Katarina Čurová2, Leonard Siegfried2.   

Abstract

Yeasts frequently colonize non-sterile sites in the body. The aim of the study was to determine distribution in clinical samples and antifungal susceptibility to five antifungals. From January 2013 through June 2015, 800 isolates were obtained from intensive care unit patients. Candida albicans (58.9%), Candida glabrata (20.4%), Candida krusei (8.6%), and Candida parapsilosis (3.6%) were the leading species. Majority of the C. albicans isolates were susceptible to the fluconazole. Elevated voriconazole minimal inhibitory concentrations (MICs) were observed in isolates exhibiting high fluconazole MICs, most frequently in C. glabrata. Isolates with echinocandins MICs suggesting reduced susceptibility were only sporadic cases with the exception of Trichosporon spp. The amphotericin B MICs were slightly higher for some C. krusei.

Entities:  

Keywords:  Antifungal Drug; Caspofungin; Invasive Fungal Infection; Triazole; Voriconazole

Mesh：

Substances：

Year:  2017        PMID： 28361459     DOI： 10.1007/s12223-017-0525-8

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN： 0015-5632            Impact factor:   2.099


  40 in total

1.  Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group.

Authors:  V Krcméry; G Kovacicová
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

Review 2.  The changing face of fungal infections in health care settings.

Authors:  Scott K Fridkin
Journal:  Clin Infect Dis       Date:  2005-10-13       Impact factor: 9.079

3.  Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

Review 5.  Invasive fungal infections in the ICU.

Authors:  Shmuel Shoham; Shilpa Marwaha
Journal:  J Intensive Care Med       Date:  2009-12-01       Impact factor: 3.510

Review 6.  Global trends in the distribution of Candida species causing candidemia.

Authors:  J Guinea
Journal:  Clin Microbiol Infect       Date:  2014-03-06       Impact factor: 8.067

Review 7.  Anidulafungin for the treatment of invasive candidiasis.

Authors:  A Mayr; M Aigner; C Lass-Flörl
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

8.  Resistance mechanisms in clinical isolates of Candida albicans.

Authors:  Theodore C White; Scott Holleman; Francis Dy; Laurence F Mirels; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 9.  Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review.

Authors:  Matthew E Falagas; Nikos Roussos; Konstantinos Z Vardakas
Journal:  Int J Infect Dis       Date:  2010-08-24       Impact factor: 3.623

10.  Shifting patterns in the epidemiology of nosocomial Candida infections.

Authors:  David R Snydman
Journal:  Chest       Date:  2003-05       Impact factor: 9.410
View more
  2 in total

1.  Promising antifungal activity of new oxadiazole against Candida krusei.

Authors:  Daniella Renata Faria; Karina Mayumi Sakita; Isis Regina Grenier Capoci; Glaucia Sayuri Arita; Franciele Abigail Vilugron Rodrigues-Vendramini; Admilton Gonçalves de Oliveira Junior; Maria Sueli Soares Felipe; Patrícia de Souza Bonfim de Mendonça; Terezinha Inez Estivalet Svidzinski; Erika Seki Kioshima
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

Review 2.  Trichosporon inkin meningitis in Northeast Brazil: first case report and review of the literature.

Authors:  Eveline Pipolo Milan; Walicyranison Plinio Silva-Rocha; Jéssica Jacinto Salviano de Almeida; Tatiane Uetti Gomes Fernandes; André Luciano de Araújo Prudente; Matheus Firmino de Azevedo; Elaine Cristina Francisco; Analy Salles de Azevedo Melo; Arnaldo Lopes Colombo; Guilherme Maranhão Chaves
Journal:  BMC Infect Dis       Date:  2018-09-18       Impact factor: 3.090
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.